Porous Se@SiO2 nanospheres attenuate cisplatin-induced acute kidney injury via activation of Sirt1

Toxicol Appl Pharmacol. 2019 Oct 1:380:114704. doi: 10.1016/j.taap.2019.114704. Epub 2019 Aug 7.

Abstract

Cisplatin (CDDP) is the most commonly used chemotherapeutic drug and has an irreplaceable role in cancer treatment. However, CDDP-induced acute kidney injury (AKI) greatly limits its use. Abundant evidence has confirmed that apoptosis contributes to AKI caused by CDDP administration. The nanoparticle form of selenium, also known as Se@SiO2 nanocomposites (NPs), has been proven to be a potential agent to prevent apoptotic cell death. In this article, we established acute kidney injury models in vivo via a single injection of CDDP and used human kidney 2 (HK-2) cells for experiments in vitro. We demonstrated that NPs can improve CDDP-induced renal dysfunction. In addition, therapy with NPs attenuated apoptosis in cells and kidney tissues treated with CDDP. In terms of mechanism, we discovered that Sirt1, a deacetylase with an important role in CDDP-induced acute kidney injury, was remarkedly increased after NPs pretreatment, and the anti-apoptotic effect of the NPs was markedly abrogated after the inhibition of Sirt1. The results linked the protective effect of NPs on nephrotoxicity with Sirt1, suggesting the potential clinical importance of nanomaterials in alleviating the side effects of chemotherapy.

Keywords: Acute kidney injury; Apoptosis; Cisplatin; Nanospheres; Sirt1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / pathology
  • Animals
  • Antineoplastic Agents / adverse effects*
  • Cell Line
  • Cisplatin / adverse effects*
  • Female
  • Humans
  • Interleukin-6 / metabolism
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Mice, Inbred C57BL
  • Nanospheres / therapeutic use*
  • Porosity
  • Protective Agents / pharmacokinetics
  • Protective Agents / therapeutic use*
  • Selenium / pharmacokinetics
  • Selenium / therapeutic use*
  • Silicon Dioxide / pharmacokinetics
  • Silicon Dioxide / therapeutic use*
  • Sirtuin 1 / genetics
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antineoplastic Agents
  • Interleukin-6
  • Protective Agents
  • Tnf protein, mouse
  • Tumor Necrosis Factor-alpha
  • interleukin-6, mouse
  • Silicon Dioxide
  • Sirtuin 1
  • Selenium
  • Cisplatin